{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:05:47Z","timestamp":1793423147972,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejogrb.2025.114889","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:44:46Z","timestamp":1765471486000},"page":"114889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of relugolix therapy for symptomatic uterine fibroids: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"318","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7551-7036","authenticated-orcid":false,"given":"FNU","family":"Kalpina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Taj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabia","family":"Shujaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maimoona","family":"Qayyum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shaheer","family":"Bin Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2025.114889_b0005","doi-asserted-by":"crossref","unstructured":"Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Primers [Internet]. 2016 Jun 23 [cited 2025 Jul 21];2. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27335259\/.","DOI":"10.1038\/nrdp.2016.43"},{"key":"10.1016\/j.ejogrb.2025.114889_b0010","doi-asserted-by":"crossref","unstructured":"Li Z, Maeda D, Kudo-Asabe Y, Tamura D, Nanjo H, Hayashi A, et al. MED12 is frequently mutated in ovarian and other adnexal leiomyomas. Hum Pathol [Internet]. 2018 Nov 1 [cited 2025 Jul 21];81:89\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29944972\/.","DOI":"10.1016\/j.humpath.2018.06.013"},{"key":"10.1016\/j.ejogrb.2025.114889_b0015","unstructured":"ElKafas H, Ali M, Al-Hendy A. Leiomyoma. Encyclopedia of Reproduction: Volume 1-6, Second Edition [Internet]. 2023 Jul 17 [cited 2025 Jul 21];4:101\u20135. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538273\/."},{"key":"10.1016\/j.ejogrb.2025.114889_b0020","doi-asserted-by":"crossref","unstructured":"Attia AM, Ibrahim MM, Abou-Setta AM. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence [Internet]. 2013 [cited 2025 Dec 4];7:777\u201385. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23990713.","DOI":"10.2147\/PPA.S36948"},{"key":"10.1016\/j.ejogrb.2025.114889_b0025","doi-asserted-by":"crossref","unstructured":"Kashani BN, Centini G, Morelli SS, Weiss G, Petraglia F. Role of medical management for uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol [Internet]. 2016 Jul 1 [cited 2025 Jul 21];34:85\u2013103. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26796059\/.","DOI":"10.1016\/j.bpobgyn.2015.11.016"},{"key":"10.1016\/j.ejogrb.2025.114889_b0030","doi-asserted-by":"crossref","unstructured":"Arjona Ferreira JC, Migoya E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. F S Rep [Internet]. 2022 Jun 1 [cited 2025 Jul 21];4(2 Suppl):73. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10201285\/.","DOI":"10.1016\/j.xfre.2022.11.010"},{"key":"10.1016\/j.ejogrb.2025.114889_b0035","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med [Internet]. 2009 Jul [cited 2025 Jul 21];6(7). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19621070\/.","DOI":"10.1371\/journal.pmed.1000100"},{"key":"10.1016\/j.ejogrb.2025.114889_b0040","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. The BMJ [Internet]. 2019 [cited 2025 Jul 22];366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31462531\/.","DOI":"10.1136\/bmj.l4898"},{"key":"10.1016\/j.ejogrb.2025.114889_b0045","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health [Internet]. 2019 Nov 1 [cited 2025 Jul 22];22(4):153\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31563865\/.","DOI":"10.1136\/ebmental-2019-300117"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114889_b0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2307\/2531052","article-title":"Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models","volume":"42","author":"Robins","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.ejogrb.2025.114889_b0055","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials [Internet]. 1986 [cited 2025 Jul 22];7(3):177\u201388. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3802833\/.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"10.1016\/j.ejogrb.2025.114889_b0060","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med [Internet]. 2002 Jun 15 [cited 2025 Jul 22];21(11):1539\u201358. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12111919\/.","DOI":"10.1002\/sim.1186"},{"key":"10.1016\/j.ejogrb.2025.114889_b0065","unstructured":"Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis | Cochrane [Internet]. [cited 2025 Jul 22]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13."},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114889_b0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114889_b0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114889_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73151-y","article-title":"Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study","volume":"14","author":"Muzii","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2025.114889_b0085","series-title":"Obstetrics and Gynecology","first-page":"423","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","author":"Osuga","year":"2019"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114889_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-021-01475-2","article-title":"Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial","volume":"21","author":"Hoshiai","year":"2021","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ejogrb.2025.114889_b0095","doi-asserted-by":"crossref","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews [Internet]. 2022 Jun 1 [cited 2025 Jul 22];18(2):e1230. Available from: \/doi\/pdf\/10.1002\/cl2.1230.","DOI":"10.1002\/cl2.1230"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114889_b0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.52054\/FVVO.2025.142","article-title":"Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids","volume":"17","author":"De Angelis","year":"2025","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1016\/j.ejogrb.2025.114889_b0105","doi-asserted-by":"crossref","unstructured":"Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, et al. Relugolix combination therapy in Black\/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol [Internet]. 2024 Feb 1 [cited 2025 Jul 22];230(2):237.e1-237.e11. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37863160\/.","DOI":"10.1016\/j.ajog.2023.10.030"},{"key":"10.1016\/j.ejogrb.2025.114889_b0110","doi-asserted-by":"crossref","unstructured":"Bulun SE. Uterine Fibroids. Longo DL, editor. New England Journal of Medicine [Internet]. 2013 Oct 3 [cited 2025 Jul 22];369(14):1344\u201355. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra1209993.","DOI":"10.1056\/NEJMra1209993"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114889_b0115","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1093\/humrep\/deq240","article-title":"Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma","volume":"25","author":"Khan","year":"2010","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114889_b0120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/AOG.0000000000005145","article-title":"Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas","volume":"141","author":"Neblett","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ejogrb.2025.114889_b0125","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-023-01269-9","article-title":"A Randomized open-label study of relugolixalone or relugolix combination therapy in premenopausal women","volume":"62","author":"Lukes","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114889_b0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40265-024-02018-3","article-title":"Relugolix\/estradiol\/norethisterone acetate: a review in endometriosis-associated pain","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114889_b0135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114889_b0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SPV.0b013e31820c99a9","article-title":"Lower urinary tract symptoms in patients with uterine fibroids: Association with fibroid location and uterine volume","volume":"17","author":"Parker-Autry","year":"2011","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.ejogrb.2025.114889_b0145","doi-asserted-by":"crossref","unstructured":"Dancz CE, Kadam P, Li C, Nagata K, \u00d6zel B. The relationship between uterine leiomyomata and pelvic floor symptoms. Int Urogynecol J [Internet]. 2013 [cited 2025 Jul 22];25(2):241. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8605900\/.","DOI":"10.1007\/s00192-013-2183-y"},{"key":"10.1016\/j.ejogrb.2025.114889_b0150","doi-asserted-by":"crossref","unstructured":"Arjona Ferreira JC, Migoya E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. F and S Reports [Internet]. 2023 Jun 1 [cited 2025 Jul 23];4(2):73\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37223761\/.","DOI":"10.1016\/j.xfre.2022.11.010"},{"key":"10.1016\/j.ejogrb.2025.114889_b0155","doi-asserted-by":"crossref","unstructured":"Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol [Internet]. 2020 Jan 1 [cited 2025 Jul 23];224(1):72.e1. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8800453\/.","DOI":"10.1016\/j.ajog.2020.07.032"},{"key":"10.1016\/j.ejogrb.2025.114889_b0160","doi-asserted-by":"crossref","unstructured":"\u0218tef\u0103nescu BI, Mihalache TI, Constantin BG, Chiran DA, Stan CI, Ionescu AA, et al. Combined relugolix treatment for highly symptomatic uterine leiomyoma patients. The Medical-Surgical Journal [Internet]. 2025 Apr 7 [cited 2025 Jul 23];129(1):144\u201351. Available from: https:\/\/www.revmedchir.ro\/index.php\/revmedchir\/article\/view\/3151.","DOI":"10.22551\/MSJ.2025.01.17"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114889_b0165","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jmig.2020.08.315","article-title":"Relugolix combination therapy improves hemoglobin levels in anemic women with uterine fibroids: results from the liberty phase 3 program","volume":"27","author":"Venturella","year":"2020","journal-title":"J Minim Invasive Gynecol"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114889_b0170","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1080\/03007995.2017.1372107","article-title":"Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey","volume":"33","author":"Soliman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejogrb.2025.114889_b0175","doi-asserted-by":"crossref","unstructured":"Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, et al. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstetrics and Gynecology [Internet]. 2022 Jun 1 [cited 2025 Jul 23];139(6):1070\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35675604\/.","DOI":"10.1097\/AOG.0000000000004787"},{"key":"10.1016\/j.ejogrb.2025.114889_b0180","doi-asserted-by":"crossref","unstructured":"Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database of Systematic Reviews [Internet]. 2017 Nov 15 [cited 2025 Jul 23];2017(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29139105\/.","DOI":"10.1002\/14651858.CD000547.pub2"},{"key":"10.1016\/j.ejogrb.2025.114889_b0185","doi-asserted-by":"crossref","unstructured":"Giudice LC, As-Sanie S, Arjona Ferreira JC, Becker CM, Abrao MS, Lessey BA, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). The Lancet [Internet]. 2022 Jun 18 [cited 2025 Jul 23];399(10343):2267\u201379. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S0140673622006225.","DOI":"10.1016\/S0140-6736(22)00622-5"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114889_b0190","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/oxfordjournals.humrep.a138762","article-title":"Endocrinology: long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin \u201cadd-back\u201d for 2 years","volume":"9","author":"Friedman","year":"1994","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114889_b0195","first-page":"73","article-title":"Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis","volume":"4","author":"Arjona Ferreira","year":"2023","journal-title":"F S Rep"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525011650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525011650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:23:54Z","timestamp":1779449034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525011650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0301211525011650"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114889","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of relugolix therapy for symptomatic uterine fibroids: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114889"}}